华熙生物(688363)：公司披露全新特定序列PDRN专利技术 Q3利润延续正增趋势

Group 1 - The core viewpoint of the article is that Huaxi Biological has disclosed a new patent technology for specific sequence PDRN, which is a significant advancement in the field of synthetic biology [1] - The newly patented product features a specific sequence PDRN that is 100% similar to the human genome, ensuring stability and controllability in molecular weight and product quality [1] - This achievement marks a breakthrough over previous methods that relied on animal extraction and microbial fermentation, providing a more stable raw material source and significantly improved purity [1] Group 2 - In Q3 2025, the company continued to maintain profit growth, with a revenue of 3.163 billion, down 18.36%, and a net profit attributable to shareholders of 252 million, down 30.29% [2] - The Q3 revenue was 903 million, down 15.16%, but the net profit attributable to shareholders increased by 55.63% to 32 million, indicating a positive trend following a profitability turning point in Q2 [2] - The gross profit margin in Q3 was 69.91%, down 2.47 percentage points, while the sales expense ratio decreased to 34.26%, the lowest in five years, due to optimized brand communication and channel structure [2]